To protect the personal health information of participants within the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO), data are only available through the PLCO study, which contributed data and specimens for this project. Interested researchers may obtain the data by submitting a request through the Cancer Data Access System website for PLCO: <https://biometry.nci.nih.gov/cdas/plco/>. Researchers may contact the PLCO study by visiting <https://prevention.cancer.gov/majorprograms/> prostate-lung-colorectal or e-mail <cdas@imsweb.com>. A PLCO data use agreement needs to be signed in order for the data to be made available.

Introduction {#sec001}
============

Diabetes is associated with significant global health and economic burden. In 2015, 415 million adults (8.3 percent of adults) had diabetes \[[@pone.0182359.ref001]\]. By 2040, it is projected that 642 million people will live with diabetes. In 2015, five million adults under the age of 80 died as a result of adult-onset diabetes worldwide, and diabetes-related global health expenditures totaled 673 billion in US dollars.

Diabetes is divided into types 1 and 2, which are associated with autoimmune destruction of pancreatic islet beta cells and with insulin resistance, respectively. The more common type 2 diabetes comprises approximately 90 to 95% of adult-onset cases and is linked with numerous health-related and demographic characteristics including obesity, family history of diabetes, older age, physical inactivity, and race and ethnicity \[[@pone.0182359.ref002]\]. In addition, diabetes is a potential risk factor for numerous complications as well as cancer at multiple sites such as pancreas, liver, biliary tract, breast, colon, rectum, urinary tract, and gynecological tract \[[@pone.0182359.ref001], [@pone.0182359.ref003], [@pone.0182359.ref004]\].

Chronic inflammation contributes to cancer risk \[[@pone.0182359.ref005], [@pone.0182359.ref006]\] and may play a role in cancer initiation and promotion among patients with type 2 diabetes and/or obesity \[[@pone.0182359.ref007]\]. Furthermore, increased levels of inflammation as measured by circulating cytokines and chemokines, white blood cell counts, and inflammatory gene polymorphisms are associated with diabetes \[[@pone.0182359.ref008]--[@pone.0182359.ref010]\]. These findings suggest that diabetes might contribute to the development of cancer via inflammation. Prior studies of inflammation-related markers and diabetes have measured a limited number of inflammatory markers, primarily C-reactive protein (CRP) and interleukin 6 (IL-6) and, more recently, anti-inflammatory cytokines \[[@pone.0182359.ref010], [@pone.0182359.ref011]\].

The objective of this study was to more broadly evaluate the associations between serologic markers of inflammation and innate immunity and self-reported diabetes using a commercially available panel of 78 inflammation-, immune-, and metabolic-related proteins.

Materials and methods {#sec002}
=====================

Study population {#sec003}
----------------

The Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO) is a randomized screening trial that recruited approximately 155,000 participants aged 55--74 years at baseline between 1992 and 2001 \[[@pone.0182359.ref012]\]. The PLCO study was approved by the Institutional Review Boards at each screening center and at the National Cancer Institute (reference number 358421, protocol number OH97CN041-KKK), and all participants gave written informed consent. Briefly, the objective of the trial was to assess the effect of prostate, lung, colorectal and ovarian cancer screening on disease-specific mortality. In addition to demographic, behavioral, and dietary information, blood samples were obtained at PLCO study baseline and at five subsequent annual visits from participants in the screening arm. Cancer diagnoses were ascertained through annual questionnaires and confirmed by medical chart abstraction and death certificate review. For prostate, lung, colorectal and ovarian cancer, diagnoses were additionally ascertained as a result of clinical follow-up after a positive screening test.

We combined data from three previous PLCO nested case-control studies (i.e., studies of lung cancer \[526 cases, 592 matched controls\], ovarian cancer \[150 cases, 149 matched controls\] and non-Hodgkin lymphoma \[NHL\] \[301 cases, 301 matched controls\]) that measured serum inflammation-, immune-, and metabolic-related marker levels using a common set of commercially available multiplex panels \[[@pone.0182359.ref006], [@pone.0182359.ref013]\]. Detailed information on the inclusion criteria, matching factors, and inflammation-related markers measured in the lung cancer, ovarian cancer and NHL case-control studies is presented in [S1 Table](#pone.0182359.s001){ref-type="supplementary-material"}. The combined dataset was limited to non-Hispanic whites (n = 152 excluded). In addition to exclusions made in the original case-control studies, individuals with a personal history of cancer prior to randomization (n = 31) and with incomplete smoking data (n = 11) were also excluded from this study on diabetes and inflammation/immune-related markers, resulting in a total of 1,819 individuals who were included in this analysis. Cancer cases were included in this analysis, as they were cancer-free at the time of blood draw, and represented a small fraction of the data after sampling weights were applied (2.8%).

Laboratory assay and analysis {#sec004}
-----------------------------

Serum specimens used for this study were collected either at baseline (89% of lung, 91% of NHL, and 8% of ovarian studies) or follow up and processed at 1200 xg for 15 minutes, frozen within 2 hours of collection, and stored at -70°C. Time and season of blood draw, but not fasting status, were recorded. These specimens were used to measure circulating levels of 86 markers (77 markers in the lung cancer study, 60 in the ovarian cancer study and 83 in the NHL study; [S2 Table](#pone.0182359.s002){ref-type="supplementary-material"}) including 4 panels of cytokines and chemokines as well as metabolic disease, soluble receptor, and cardiovascular disease panels. These markers were selected based on a methodologic study that evaluated the performance and reproducibility of multiplexed assays for measurement of inflammation markers in serum \[[@pone.0182359.ref014]\]. Markers were measured using Luminex bead-based assays (EMD Millipore, Inc., Billerica, MA) according to the manufacturer's protocols: <http://dx.doi.org/10.17504/protocols.io.hbcv62w> (cardiovascular panel), <http://dx.doi.org/10.17504/protocols.io.hvdb626> (cytokine panel 1a), <http://dx.doi.org/10.17504/protocols.io.hveb63e> (cytokine panel 1b), <http://dx.doi.org/10.17504/protocols.io.hvfb63n> (cytokine panel 2), <http://dx.doi.org/10.17504/protocols.io.hvgb63w> (cytokine panel 3), <http://dx.doi.org/10.17504/protocols.io.hvhb636> (metabolic hormone panel), and <http://dx.doi.org/10.17504/protocols.io.hvib64e> (soluble receptor panel). Concentrations were calculated using either a four- or five-parameter standard curve. Serum samples were assayed in duplicate, and averaged to calculate final concentrations. Blinded duplicates in the lung and NHL studies and duplicate measurements on study subjects in the ovarian cancer study were used to evaluate assay reproducibility through coefficients of variation (CVs) and intraclass correlation coefficients (ICCs) calculated on log-transformed values of the markers. ICCs were \>0.8 in 91% of these markers in the lung and NHL studies \[[@pone.0182359.ref006], [@pone.0182359.ref013]\], and in 78% of these markers in the ovarian cancer study \[[@pone.0182359.ref015]\]. Eight markers with \>90% of values below the lowest limit of detection (LLOD) were excluded from all analyses, resulting in 78 evaluable markers. The remaining markers had within-batch CVs \<30%.

Statistical analysis {#sec005}
--------------------

As described previously in detail \[[@pone.0182359.ref006]\] to combine data from the case-control studies, we developed sets of propensity-score-adjusted sampling weights to ensure that our analysis accounted for the particular inclusion/exclusion criteria and sampling plan for each study \[[@pone.0182359.ref016]\] ([S1 Table](#pone.0182359.s001){ref-type="supplementary-material"}). The sampling weights allowed us to include all participants with marker data (including cancer cases), and made our analysis as representative as possible of the non-Hispanic white PLCO screening arm. Sampling weights were derived from logistic regression models for the probability that an eligible screening arm participant would be selected into any given case-control study. Separate logistic regression models were conducted based on case/control status, study, and sex. Each logistic regression model included age, smoking status, smoking pack-years, and vital status on December 31, 2009. Study-specific weights were then combined for each of the five combinations of case-control studies with a common subset of panels (all 3 studies, lung and NHL, lung and ovary, NHL and ovary, and lung alone). These sampling weights were used in logistic regression models for each dichotomized marker regressed on smoking status and other confounders including age, sex, time of blood draw (PM vs. AM), and study to provide extra control for study-specific selection factors \[[@pone.0182359.ref017]\]. Simulations suggest that analyses using both weighting methods and additional regression adjustment for matching factors provide a good way to adjust for non-representative sampling in nested case-control studies \[[@pone.0182359.ref018]\]. While the three nested studies analyzed data from both non-cases and cancer cases, the blood specimens were predominantly drawn at baseline and predated any cancer diagnosis. A sensitivity analysis was also conducted examining relationships between markers and self-reported diabetes among the participants who did not go on to develop cancer.

Information regarding participant characteristics including self-reported diabetes and other prevalent conditions was collected at baseline. Participants were asked to mark Yes or No to answer the following on the baseline questionnaire: "Has a doctor ever told you that you have any of the following conditions?" followed by a list that included "Diabetes." Type of diabetes and diabetes treatment were not collected. Baseline characteristics of i) the 1,819 individuals with inflammatory marker data included in the current study, ii) the weighted population, and iii) the participants in the PLCO screening arm who met study eligibility criteria were compared. Of the 1,819 participants, five were missing information on self-reported diabetes at baseline.

Main analysis {#sec006}
-------------

The association between each of the 78 markers and self-reported diabetes was estimated in weighted logistic regression models adjusting for smoking status, age at blood draw, sex, BMI category, year of blood draw, and study of origin using standard survey regression analysis software (SAS v9.3, Cary, NC) \[[@pone.0182359.ref017]\]. A number of markers had a substantial fraction of values below the LLOD, which precluded analysis of these markers as continuous measures. Therefore, separately by study, inflammation marker levels were divided into quantiles (Q), or as detectable and undetectable if \>50% of the values were below the LLOD. To assess the trend in distribution across inflammation-related marker quantiles self-reported diabetes (yes vs. no), the *P*-value for the Wald test of the marker as an ordinal variable was examined. We identified all markers where the *P*-value was less than 5%. To account for multiple comparisons, false discovery rate (FDR) criteria of \<5% and \<10% were applied.

Several restricted analyses were performed to ensure the main findings were not affected by the population in the analyses. These included analyses 1) among individuals with and without self-reported diabetes, who did not develop cancer, 2) excluding the ovarian cancer study participants to eliminate participants with blood draws after baseline, 3) restricted to participants who had their blood drawn in the morning, and 4) including a time of blood draw (PM vs. AM) x inflammation marker multiplicative interaction term and examining the *P*-value for the Wald test of this interaction term. All models were adjusted for smoking status, age at blood draw, sex, BMI category (15 to \<25, 25 to \<30, 30+ kg/m^2^), year and time (PM vs. AM) of serum collection, and study of origin (i.e., lung cancer, ovarian cancer, or NHL study). In order to identify associations among participants with subclinical diabetes, multivariable linear regression was used to examine potential relationships between inflammation-related markers and metabolic markers, that were strongly associated with self-reported diabetes on logistic regression analysis with *P* \< 0.002 (insulin, PP, and GIP), among participants who did not report a history of diabetes. Spearman correlations were used to estimate unweighted correlations between the markers. All analyses were carried out using survey procedures in SAS 9.3 (Cary, NC).

Results {#sec007}
=======

Participant characteristics {#sec008}
---------------------------

Compared to the full PLCO screening arm (N = 58,264), individuals with inflammatory marker data included within the current analysis (N = 1,814) were more likely to be male (55.3% vs. 51.4%); older (21.7% vs. 12.7% for those ≥70 years old) and current smokers (22.8% vs. 10.0%) ([S3 Table](#pone.0182359.s003){ref-type="supplementary-material"}). Following weighting, however, the characteristics of the resulting weighted population closely resembled those of the PLCO screening arm. Following weighting, approximately 6% of individuals had self-reported diabetes (N = 3,332 weighted, N = 120 unweighted). Compared with individuals without a self-reported history of diabetes, those with self-reported diabetes were more likely to be older (31.1% versus 15.4% aged 70 years or older), overweight (40.9% versus 20.1% BMI ≥ 30), former smokers (57.7% versus 42.8%) and to have had a morning blood draw (70% versus 60.9%) ([Table 1](#pone.0182359.t001){ref-type="table"}). Distribution of blood draw time of day (PM vs. AM) did not differ by study \[% PM blood draw: 40.8% (lung cancer study), 36.7% (NHL study), 34.1% (ovarian cancer study); χ^2^ *P*-value = 0.08\].

10.1371/journal.pone.0182359.t001

###### Participant characteristics for the 1,819 individuals with inflammatory marker data and the weighted population, by self-reported diabetes.

![](pone.0182359.t001){#pone.0182359.t001g}

  Characteristic                                              Self-Reported Diabetes                               
  ----------------------------------------------------------- ------------------------ --------------- ----------- --------------
  Total                                                       1,694                    54,781          120         3,332
  Sex                                                                                                              
  Female                                                      777 (45.9)               26,763 (48.9)   34 (28.3)   1,493 (44.8)
  Male                                                        917 (54.1)               28,018 (51.1)   86 (71.7)   1,839 (55.2)
  Age Group (years)                                                                                                
  ≤59                                                         320 (18.9)               15,827 (28.9)   14 (11.7)   501 (15.0)
  60--64                                                      511 (30.2)               19,644 (35.9)   31 (25.8)   779 (23.4)
  65--69                                                      505 (29.8)               10,856 (19.8)   40 (33.3)   1,016 (30.5)
  ≥70                                                         358 (21.1)               8,453 (15.4)    35 (29.2)   1,035 (31.1)
  BMI Category (kg/m^2^)                                                                                           
  ≤25                                                         616 (36.4)               17,246 (31.5)   22 (18.3)   761 (22.9)
  25-\<30                                                     739 (43.6)               25,657 (46.8)   50 (41.7)   1,207 (36.2)
  ≥30                                                         319 (18.8)               11,034 (20.1)   47 (39.2)   1,363 (40.9)
  Smoking Status                                                                                                   
  Never                                                       517 (30.5)               25,974 (47.4)   30 (25.0)   1,172 (35.2)
  Former                                                      784 (46.3)               23,457 (42.8)   71 (59.2)   1,922 (57.7)
  Current                                                     393 (23.2)               5,350 (9.8)     19 (15.8)   238 (7.1)
  Original Case-Control Study                                                                                      
  Lung Cancer Study                                           922 (54.4)               23,477 (42.9)   74 (61.7)   931 (28.0)
  Non-Hodgkin Lymphoma Study                                  529 (31.2)               22,282 (40.7)   40 (33.3)   1,978 (59.4)
  Ovarian Cancer Study                                        243 (14.3)               9,021 (16.5)    6 (5.0)     422 (12.7)
  Case-Control Status[^a^](#t001fn002){ref-type="table-fn"}                                                        
  Case                                                        815 (48.1)               645 (1.2)       59 (49.2)   54 (1.6)
  Control                                                     879 (51.9)               54,136 (98.8)   61 (50.8)   3,278 (98.4)

After weighting, self-reported diabetes cases were older and had a higher body mass index than did people without a history of self-reported diabetes. Otherwise, participant characteristics were similar. Columns do not add to 100% due to missing data (individuals missing diabetes information, N = 5)

^a^Cases were individuals without cancer at the time of blood collection, but who developed either lung, NHL, or ovarian cancer over the course of follow-up. Controls were free of cancer of interest of each study at the time of selection.

Analysis of inflammation-, immune-, and metabolic-related markers associated with self-reported diabetes {#sec009}
--------------------------------------------------------------------------------------------------------

Out of the 78 different inflammation-, immune- and metabolic-related markers tested, 16 markers were significantly associated with self-reported diabetes at a nominal *P*-value (\<0.05) unadjusted for multiple comparisons ([Table 2](#pone.0182359.t002){ref-type="table"}). Following an FDR correction for multiple comparisons, three markers remained significantly associated at the \<5% level with a higher odds of self-reported diabetes at baseline: insulin, glucose-dependent insulinotropic peptide (or gastric inhibitory polypeptide; GIP) and pancreatic polypeptide (PP) ([Table 2](#pone.0182359.t002){ref-type="table"}). In addition, higher levels of the cytokine receptors, sIL-6R and sTNFR1, and the chemokines, CCL19, CCL20, CCL21, and CXCL11, were also associated with a history of self-reported diabetes at the \<10% level. Of note, there were no participants with self-reported diabetes with insulin levels in the first quantile; subsequently, the first and second quantiles were combined for all analyses. Our results did not materially change in analyses restricted to controls (patients who did not develop cancer in the PLCO screening trial), to baseline serum specimens, or to specimens collected in the AM, as well as analyses adjusted for blood draw time of day (PM vs. AM) in the model.

10.1371/journal.pone.0182359.t002

###### Associations between inflammation-, immune-, and metabolic-related markers and self-reported diabetes.

![](pone.0182359.t002){#pone.0182359.t002g}

  Marker        Quantile (Q)   Total (N)   Self-Reported Diabetes N (%)   POR (95% CI)[^a^](#t002fn002){ref-type="table-fn"}   *P-trend*
  ------------- -------------- ----------- ------------------------------ ---------------------------------------------------- ------------
  **Insulin**   Q1             193         0                              \-                                                   
                Q2             198         4 (2.0)                        1.00                                                 
                Q3             216         11 (5.1)                       2.3 (0.5--10.1)                                      
                Q4             211         31 (14.7)                      12.2 (3.3--45.5)                                     *0*.*0003*
  **GIP**       Q1             196         3 (1.5)                        1.00                                                 
                Q2             230         12 (5.2)                       4.0 (0.7--22.2)                                      
                Q3             206         11 (5.3)                       4.2 (0.8--21.7)                                      
                Q4             186         20 (10.8)                      15.9 (3.3--77.2)                                     *0*.*0007*
  **PP**        Q1             194         5 (2.6)                        1.00                                                 
                Q2             216         7 (3.2)                        1.7 (0.3--9.9)                                       
                Q3             185         14 (7.6)                       9.2 (1.9--43.8)                                      
                Q4             223         20 (9.0)                       5.8 (1.2--28.0)                                      *0*.*001*
  sIL-6R        Q1             489         25 (5.1)                       1.00                                                 
                Q2             466         28 (6.0)                       1.6 (0.6--4.4                                        
                Q3             373         24 (6.4)                       1.3 (0.4--4.4)                                       
                Q4             485         43 (8.9)                       4.3 (1.7--10.6)                                      *0*.*003*
  CCL21         Q1             364         23 (6.3)                       1.00                                                 
                Q2             381         20 (5.3)                       1.3 (0.4--4.6)                                       
                Q3             400         31 (7.8)                       3.6 (1.2--10.5)                                      
                Q4             419         40 (9.5)                       4.1 (1.4--11.9)                                      *0*.*004*
  CCL20         Q1             521         22 (4.2)                       1.00                                                 
                Q2             311         22 (7.1)                       0.7 (0.2--2.4)                                       
                Q3             376         25 (6.6)                       1.5 (0.5--4.6)                                       
                Q4             356         45 (12.6)                      4.7 (1.7--12.9)                                      *0*.*005*
  sTNFR1        Q1             458         26 (5.7)                       1.00                                                 
                Q2             389         14 (3.6)                       0.1 (0.0--0.6)                                       
                Q3             457         34 (7.4)                       1.7 (0.7--4.3)                                       
                Q4             509         46 (9.0)                       2.3 (0.96--5.3)                                      *0*.*006*
  CXCL11        Q1             402         21 (5.2)                       1.00                                                 
                Q2             428         34 (7.9)                       3.1 (1.2--8.5)                                       
                Q3             383         26 (6.8)                       2.1 (0.7--6.7)                                       
                Q4             351         33 (9.4)                       5.8 (2.1--16.2)                                      *0*.*007*
  CCL19         Q1             405         15 (3.7)                       1.00                                                 
                Q2             368         26 (7.1)                       1.6 (0.5--5.3)                                       
                Q3             354         28 (7.9)                       1.3 (0.4--4.2)                                       
                Q4             437         45 (10.3)                      4.7 (1.5--15.1)                                      *0*.*01*
  sTNFR2        Q1             403         20 (5.0)                       1.00                                                 
                Q2             418         20 (4.8)                       0.5 (0.2--1.6)                                       
                Q3             454         31 (6.8)                       0.7 (0.3--1.8)                                       
                Q4             538         49 (9.1)                       2.7 (1.2--6.5)                                       *0*.*01*
  CXCL10        Q1             505         25 (5.0)                       1.00                                                 
                Q2             419         19 (4.5)                       1.4 (0.5--4.1)                                       
                Q3             418         29 (6.9)                       1.5 (0.6--4.0)                                       
                Q4             471         47 (10.0)                      3.2 (1.3--8.0)                                       *0*.*02*
  CXCL6         Q1             383         19 (5.0)                       1.00                                                 
                Q2             378         29 (7.7)                       1.1 (0.4--3.1)                                       
                Q3             402         31 (7.7)                       1.0 (0.4--2.8)                                       
                Q4             401         35 (8.7)                       3.3 (1.2--9.1)                                       *0*.*03*
  Amylin        Q1             371         19 (5.1)                       1.00                                                 
                Q2             152         6 (3.9)                        0.8 (0.2--3.1)                                       
                Q3             147         11 (7.5)                       2.8 (0.9--8.8)                                       
                Q4             148         10 (6.8)                       2.9 (0.9--9.6)                                       *0*.*04*
  sIL-RII       Q1             464         24 (5.2)                       1.00                                                 
                Q2             482         24 (5.0)                       1.5 (0.6--4.0)                                       
                Q3             388         26 (6.7)                       1.9 (0.7--5.1)                                       
                Q4             479         46 (9.6)                       2.8 (1.1--7.4)                                       *0*.*04*
  Glucagon      Q1             648         31 (4.8)                       1.00                                                 
                Q2             170         15 (8.8)                       2.7 (1.0--7.0)                                       
                Q3             \-          \-                             \-                                                   
                Q4             \-          \-                             \-                                                   *0*.*04*
  C-peptide     Q1             197         9 (4.6)                        1.00                                                 
                Q2             199         8 (4.0)                        0.9 (0.2--3.9)                                       
                Q3             209         9 (4.3)                        0.09 (0.2--3.7)                                      
                Q4             213         20 (9.4)                       3.5 (0.95--13.1)                                     *0*.*05*
  IL-8          Q1             402         23 (5.7)                       1.00                                                 
                Q2             425         27 (6.4)                       2.1 (0.7--6.0)                                       
                Q3             487         33 (6.8)                       2.2 (0.8--5.9)                                       
                Q4             504         37 (7.4)                       2.6 (1.0--6.3)                                       *0*.*06*
  Leptin        Q1             238         8 (3.4)                        1.00                                                 
                Q2             193         11 (5.7)                       2.5 (0.5--12.1)                                      
                Q3             215         17 (7.9)                       6.5 (1.2--36.6)                                      
                Q4             175         10 (5.8)                       5.3 (0.7--41.6)                                      *0*.*07*
  EGF           Q1             517         50 (9.7)                       1.00                                                 
                Q2             381         27 (7.1)                       1.3 (0.5--3.1)                                       
                Q3             495         29 (5.9)                       0.8 (0.3--2.0)                                       
                Q4             425         14 (3.3)                       0.4 (0.1--1.2)                                       *0*.*08*
  CCL13         Q1             368         19 (5.2)                       1.00                                                 
                Q2             404         18 (4.5)                       1.4 (0.5--4.5)                                       
                Q3             388         36 (9.3)                       1.7 (0.6--5.3)                                       
                Q4             409         41 (10.1)                      2.7 (0.9--7.9)                                       *0*.*08*
  IL-16         Q1             624         47 (7.5)                       1.00                                                 
                Q2             295         15 (5.1)                       0.6 (0.2--1.7)                                       
                Q3             307         20 (6.5)                       0.9 (0.3--2.5)                                       
                Q4             343         32 (9.4)                       2.0 (0.9--4.5)                                       *0*.*08*
  CCL27         Q1             379         36 (9.6)                       1.00                                                 
                Q2             400         27 (6.8)                       0.8 (0.3--2.2)                                       
                Q3             370         32 (8.7)                       0.7 (0.3--1.8)                                       
                Q4             420         19 (4.5)                       0.4 (0.1--1.1)                                       *0*.*09*
  CCL8          Q1             443         31 (7.0)                       1.00                                                 
                Q2             371         30 (8.1)                       2.3 (0.8--6.2)                                       
                Q3             354         19 (5.4)                       2.0 (0.7--5.8)                                       
                Q4             401         34 (8.5)                       2.7 (1.0--7.6)                                       *0*.*11*
                                           *P-trend*                                                                           
  CCL24         Q1             356         18 (5.1)                       1.00                                                 
                Q2             445         35 (7.9)                       2.1 (0.7--6.3)                                       
                Q3             357         26 (7.3)                       2.0 (0.7--6.1)                                       
                Q4             411         35 (8.5)                       2.5 (0.9--7.1)                                       *0*.*11*
                                           *P-trend*                      *0*.*11*                                             
  GLP-1         Q1             619         30 (4.9)                       1.00                                                 
                Q2             202         16 (7.9)                       2.1 (0.8--5.4)                                       *0*.*13*
                Q3             \-          \-                             \-                                                   
                Q4             \-          \-                             \-                                                   
                                           *P-trend*                                                                           
  sVEGFR2       Q1             358         17 (4.8)                       1.00                                                 
                Q2             489         35 (7.2)                       1.0 (0.4--2.6)                                       
                Q3             518         33 (6.4)                       1.5 (0.6--3.9)                                       
                Q4             453         35 (7.8)                       2.0 (0.7--5.3)                                       *0*.*14*
  G-CSF         Q1             996         59 (5.9)                       1.00                                                 
                Q2             433         31 (7.2)                       1.0 (0.4--2.5)                                       
                Q3             389         30 (7.8)                       2.0 (0.9--4.5)                                       *0*.*14*
                Q4             \-          \-                             \-                                                   
  IFN-γ         Q1             1019        65 (6.4)                       1.00                                                 
                Q2             351         23 (6.6)                       1.3 (0.5--3.0)                                       
                Q3             445         32 (7.2)                       1.8 (0.8--3.8)                                       *0*.*15*
                Q4             \-          \-                             \-                                                   
  TNF-α         Q1             443         20 (4.7)                       1.00                                                 
                Q2             402         33 (8.2)                       1.5 (0.5--4.2)                                       
                Q3             442         24 (5.4)                       1.1 (0.4--3.1)                                       
                Q4             541         43 (8.0)                       2.2 (0.8--5.9)                                       *0*.*17*
  CXCL5         Q1             361         18 (5.0)                       1.00                                                 
                Q2             417         35 (8.4)                       2.6 (0.9--7.2)                                       
                Q3             333         28 (8.5)                       2.1 (0.8--5.9)                                       
                Q4             458         33 (7.2)                       2.7 (0.9--7.7)                                       *0*.*17*
  PYY           Q1             597         28 (4.7)                       1.00                                                 
                Q2             118         9 (7.7)                        2.6 (0.8--8.8)                                       
                Q3             106         9 (8.5)                        1.9 (0.5--6.9)                                       *0*.*18*
                Q4             \-          \-                             \-                                                   
  CXCL9         Q1             386         28 (7.3)                       1.00                                                 
                Q2             318         19 (6.0)                       0.8 (0.2--2.4)                                       
                Q3             363         25 (6.9)                       1.3 (0.5--3.5)                                       
                Q4             502         42 (8.4)                       1.8 (0.7--4.8)                                       *0*.*18*
  CX3CL1        Q1             1520        97 (6.4)                       1.00                                                 
                Q2             298         23 (7.7)                       1.7 (0.8--3.8)                                       *0*.*20*
                Q3             \-          \-                             \-                                                   
                Q4             \-          \-                             \-                                                   
  CXCL13        Q1             332         18 (5.4)                       1.00                                                 
                Q2             356         27 (7.6)                       1.3 (0.4--4.1)                                       
                Q3             375         31 (8.3)                       1.3 (0.4--4.4)                                       
                Q4             506         38 (7.5)                       2.2 (0.7--7.2)                                       *0*.*21*
  IL-1α         Q1             1489        93 (6.3)                       1.00                                                 
                Q2             329         27 (8.2)                       1.6 (0.8--3.4)                                       *0*.*22*
                Q3             \-          \-                             \-                                                   
                Q4             \-          \-                             \-                                                   
  IL-5          Q1             1572        102 (6.5)                      1.00                                                 
                Q2             246         18 (7.3)                       1.6 (0.7--3.6)                                       *0*.*24*
                Q3             \-          \-                             \-                                                   
                Q4             \-          \-                             \-                                                   
  IL-17         Q1             890         61 (6.9)                       1.00                                                 
                Q2             290         21 (7.2)                       0.9 (0.3--2.5)                                       
                Q3             292         14 (4.8)                       0.7 (0.3--1.8)                                       
                Q4             346         24 (6.9)                       1.8 (0.8--4.2)                                       *0*.*31*
  IL-11         Q1             1179        84 (7.2)                       1.00                                                 
                Q2             390         30 (7.7)                       1.5 (0.7--3.0)                                       *0*.*32*
                Q3             \-          \-                             \-                                                   
                Q4             \-          \-                             \-                                                   
  CCL15         Q1             340         20 (5.9)                       1.00                                                 
                Q2             386         23 (6.0)                       0.6 (0.2--1.9)                                       
                Q3             380         27 (7.1)                       1.1 (0.4--2.9)                                       
                Q4             463         44 (9.5)                       1.4 (0.5--4.0)                                       *0*.*32*
  IL-12p40      Q1             1477        95 (6.5)                       1.00                                                 
                Q2             341         25 (7.4)                       1.4 (0.7--2.9)                                       *0*.*36*
                Q3             \-          \-                             \-                                                   
                Q4             \-          \-                             \-                                                   
  CCL7          Q1             1551        102 (6.6)                      1.00                                                 
                Q2             267         18 (6.8)                       0.7 (0.3--1.6)                                       *0*.*36*
                Q3             \-          \-                             \-                                                   
                Q4             \-          \-                             \-                                                   
  CXCL1,2,3     Q1             479         35 (7.3)                       1.00                                                 
                Q2             354         20 (5.7)                       1.0 (0.4--2.7)                                       
                Q3             482         32 (6.6)                       1.1 (0.4--2.9)                                       
                Q4             503         33 (6.6)                       1.5 (0.6--3.9)                                       *0*.*38*
  SAA           Q1             235         13 (5.6)                       1.00                                                 
                Q2             238         19 (8.0)                       0.3 (0.1--1.1)                                       
                Q3             230         21 (9.1)                       1.1 (0.4--3.5)                                       
                Q4             291         21 (7.2)                       0.4 (0.1--1.3)                                       *0*.*42*
  SCF           Q1             841         61 (7.3)                       1.00                                                 
                Q2             335         22 (6.6)                       0.6 (0.3--1.5)                                       
                Q3             393         31 (7.9)                       0.7 (0.3--1.8)                                       *0*.*43*
                Q4             \-          \-                             \-                                                   
  IL-12p70      Q1             1534        96 (6.3)                       1.00                                                 
                Q2             287         24 (8.5)                       1.4 (0.6--3.2)                                       *0*.*44*
                Q3             \-          \-                             \-                                                   
                Q4             \-          \-                             \-                                                   
  CCL2          Q1             423         24 (5.7)                       1.00                                                 
                Q2             408         32 (7.8)                       1.0 (0.4--2.4)                                       
                Q3             451         28 (6.2)                       0.7 (0.3--2.1)                                       
                Q4             536         36 (6.8)                       1.5 (0.6--3.7)                                       *0*.*44*
  IL-1β         Q1             1350        86 (6.4)                       1.00                                                 
                Q2             260         19 (7.3)                       1.2 (0.5--2.9)                                       
                Q3             208         15 (7.2)                       1.4 (0.6--3.5)                                       *0*.*44*
                Q4             \-          \-                             \-                                                   
  sEGFR         Q1             458         27 (5.9)                       1.00                                                 
                Q2             456         32 (7.1)                       1.1 (0.4--2.9)                                       
                Q3             517         37 (7.2)                       1.6 (0.6--4.3)                                       
                Q4             387         24 (6.2)                       1.3 (0.5--3.3)                                       *0*.*46*
                                           *P-trend*                                                                           
  FGF-2         Q1             1257        79 (6.3)                       1.00                                                 
                Q2             284         19 (6.7)                       1.1 (0.4--2.8)                                       
                Q3             277         22 (7.9)                       1.4 (0.6--3.2)                                       *0*.*47*
                Q4             \-          \-                             \-                                                   
  CCL11         Q1             377         23 (6.1)                       1.00                                                 
                Q2             427         25 (5.9)                       1.4 (0.6--3.4)                                       
                Q3             455         32 (7.1)                       1.7 (0.6--4.7)                                       
                Q4             599         40 (7.2)                       1.3 (0.5--3.2)                                       *0*.*47*
  TGF-α         Q1             451         33 (7.3)                       1.00                                                 
                Q2             390         29 (7.4)                       1.5 (0.5--4.2)                                       
                Q3             470         24 (5.1)                       1.1 (0.4--3.1)                                       
                Q4             507         34 (6.8)                       2.2 (0.8--5.9)                                       *0*.*48*
  IL-6          Q1             1287        81 (6.3)                       1.00                                                 
                Q2             266         22 (8.3)                       1.0 (0.4--2.3)                                       
                Q3             265         17 (6.4)                       1.4 (0.6--3.4)                                       *0*.*49*
                Q4             \-          \-                             \-                                                   
  IL-1RA        Q1             1411        92 (6.5)                       1.00                                                 
                Q2             407         28 (6.9)                       1.3 (0.6--2.6)                                       *0*.*50*
                Q3             \-          \-                             \-                                                   
                Q4             \-          \-                             \-                                                   
  IL-2          Q1             1392        86 (6.2)                       1.00                                                 
                Q2             426         34 (8.0)                       1.3 (0.6--2.6)                                       *0*.*53*
                Q3             \-          \-                             \-                                                   
                Q4             \-          \-                             \-                                                   
  CRP           Q1             214         8 (3.8)                        1.00                                                 
                Q2             287         17 (5.9)                       1.3 (0.4--4.8)                                       
                Q3             359         26 (7.2)                       1.3 (0.3--4.9)                                       
                Q4             383         29 (7.6)                       0.6 (0.1--3.3)                                       *0*.*53*
  GM-CSF        Q1             1200        77 (6.4)                       1.00                                                 
                Q2             303         18 (5.9)                       0.7 (0.3--1.8)                                       
                Q3             315         35 (7.9)                       1.5 (0.6--3.4)                                       *0*.*56*
                Q4             \-          \-                             \-                                                   
  TSLP          Q1             1243        89 (7.2)                       1.00                                                 
                Q2             326         25 (7.7)                       0.8 (0.3--1.8)                                       *0*.*57*
                Q3             \-          \-                             \-                                                   
                Q4             \-          \-                             \-                                                   
  VEGF          Q1             675         40 (5.9)                       1.00                                                 
                Q2             339         30 (8.9)                       1.5 (0.6--4.0)                                       
                Q3             360         22 (6.1)                       1.2 (0.5--3.0)                                       
                Q4             444         28 (6.4)                       0.7 (0.3--1.9)                                       *0*.*63*
  SAP           Q1             190         10 (5.3)                       1.00                                                 
                Q2             216         18 (8.3)                       2.4 (0.5--12.4)                                      
                Q3             248         15 (6.1)                       2.2 (0.5--10.0)                                      
                Q4             340         31 (9.1)                       0.9 (0.2--3.9)                                       *0*.*69*
  CCL17         Q1             322         40 (12.5)                      1.00                                                 
                Q2             351         17 (4.8)                       0.3 (0.1--1.0)                                       
                Q3             423         25 (5.9)                       0.5 (0.2--1.3)                                       
                Q4             473         32 (6.8)                       0.8 (0.3--2.3)                                       *0*.*70*
  sGP130        Q1             455         19 (4.2)                       1.00                                                 
                Q2             449         29 (6.5)                       1.0 (0.4--2.7)                                       
                Q3             454         35 (7.7)                       0.9 (0.3--2.4)                                       
                Q4             460         37 (8.1)                       1.3 (0.5--3.5)                                       *0*.*71*
  CCL3          Q1             1565        106 (6.8)                      1.00                                                 
                Q2             253         14 (5.6)                       0.9 (0.4--2.1)                                       
                Q3             \-          \-                             \-                                                   
                Q4             \-          \-                             \-                                                   *0*.*74*
  IL-10         Q1             1337        85 (6.4)                       1.00                                                 
                Q2             283         22 (7.8)                       1.0 (0.4--2.3)                                       
                Q3             198         13 (6.6)                       1.2 (0.5--3.0)                                       
                Q4             \-          \-                             \-                                                   *0*.*76*
  TRAIL         Q1             418         32 (7.7)                       1.00                                                 
                Q2             320         31 (9.8)                       0.8 (0.3--2.0)                                       
                Q3             417         20 (4.8)                       0.4 (0.2--1.1)                                       
                Q4             414         31 (7.5)                       1.0 (0.4--2.6)                                       *0*.*78*
  IL-4          Q1             1407        93 (6.6)                       1.00                                                 
                Q2             411         27 (6.6)                       1.1 (0.5--2.5)                                       *0*.*78*
                Q3             \-          \-                             \-                                                   
                Q4             \-          \-                             \-                                                   
                                           *P-trend*                                                                           
  IL-7          Q1             1383        93 (6.7)                       1.00                                                 
                Q2             435         27 (6.2)                       0.9 (0.4--2.1)                                       *0*.*79*
                Q3             \-          \-                             \-                                                   
                Q4             \-          \-                             \-                                                   
  sVEGFR3       Q1             447         23 (5.2)                       1.00                                                 
                Q2             468         31 (6.6)                       1.0 (0.4--2.8)                                       
                Q3             441         35 (8.0)                       1.7 (0.7--4.3)                                       
                Q4             462         31 (6.7)                       0.9 (0.3--2.8)                                       *0*.*83*
  CCL22         Q1             416         36 (8.7)                       1.00                                                 
                Q2             402         28 (7.0)                       1.0 (0.4--2.5)                                       
                Q3             434         21 (4.9)                       0.9 (0.4--2.3)                                       
                Q4             566         35 (6.2)                       0.9 (0.3--2.5)                                       *0*.*85*
  IL-15         Q1             1489        98 (6.6)                       1.00                                                 
                Q2             329         22 (6.7)                       1.1 (0.5--2.3)                                       *0*.*86*
                Q3             \-          \-                             \-                                                   
                Q4             \-          \-                             \-                                                   
  CXCL12        Q1             381         29 (7.6)                       1.00                                                 
                Q2             441         31 (7.1)                       0.7 (0.2--2.2)                                       
                Q3             401         25 (6.3)                       0.5 (0.2--1.4)                                       
                Q4             346         29 (8.4)                       1.3 (0.5--3.2)                                       *0*.*86*
  IFN-α2        Q1             1479        103 (6.5)                      1.00                                                 
                Q2             239         17 (7.1)                       1.1 (0.4--2.6)                                       *0*.*88*
                Q3             \-          \-                             \-                                                   
                Q4             \-          \-                             \-                                                   
  CCL4          Q1             517         40 (7.8)                       1.00                                                 
                Q2             400         25 (6.3)                       0.6 (0.2--1.6)                                       
                Q3             429         24 (5.6)                       0.5 (0.2--1.4)                                       
                Q4             472         31 (6.6)                       1.1 (0.5--2.8)                                       *0*.*90*
  TPO           Q1             990         75 (7.6)                       1.00                                                 
                Q2             286         11 (3.9)                       1.0 (0.3--2.9)                                       
                Q3             293         28 (9.6)                       1.1 (0.4--2.7)                                       *0*.*91*
                Q4             \-          \-                             \-                                                   
  IL-29         Q1             1327        95 (7.2)                       1.00                                                 
                Q2             242         19 (7.9)                       1.0 (0.4--2.5)                                       *0*.*92*
                Q3             \-          \-                             \-                                                   
                Q4             \-          \-                             \-                                                   
  sIL-4R        Q1             478         35 (7.4)                       1.00                                                 
                Q2             419         26 (6.2)                       0.6 (0.2--1.5)                                       
                Q3             430         32 (7.4)                       1.9 (0.8--4.8)                                       
                Q4             491         27 (5.5)                       0.6 (0.3--1.6)                                       *0*.*93*
  TNF-β         Q1             1353        88 (6.5)                       1.00                                                 
                Q2             239         17 (7.1)                       1.1 (0.5--2.7)                                       
                Q3             226         15 (6.6)                       1.0 (0.4--2.5)                                       *0*.*93*
                Q4             \-          \-                             \-                                                   
  sCD40L        Q1             254         21 (8.3)                       1.00                                                 
                Q2             244         19 (7.8)                       1.5 (0.5--5.0)                                       
                Q3             1320        80 (6.1)                       1.1 (0.5--2.8)                                       *0*.*94*
                Q4             \-          \-                             \-                                                   
  IL-33         Q1             1226        81 (6.6)                       1                                                    
                Q2             343         33 (9.6)                       1.0 (0.4--2.2)                                       *0*.*99*
                Q3             \-          \-                             \-                                                   

Markers in bold, including metabolic-related markers, retained statistical significance of associations with self-reported diabetes with a false discovery rate \<5% (*P*≤0.002).

^a^Adjusted for smoking, age at blood draw, gender, BMI, year of blood draw and study of origin

Abbreviations: EGF, epidermal growth factor; VEGF, vascular endothelial growth factor; FGF-2, basic fibroblast growth factor; CCL, chemokine C-C motif ligand; CXCL, chemokine C-X-C motif ligand; IL, interleukin; R, receptor; sVEGFR, soluble vascular endothelial growth factor receptor; sTNFR, soluble tumor necrosis factor receptor; PP, pancreatic polypeptide; sIL-R, soluble interleukin receptor; TRAIL, TNF-related apoptosis-inducing ligand; GIP, gastric inhibitory polypeptide; GM-CSF, granulocyte-macrophage colony-stimulating factor; sEGFR, soluble epidermal growth factor receptor; IFN, interferon; G-CSF, granulocyte colony-stimulating factor; TSLP, thymic stromal lymphopoietin; TPO, thrombopoietin; sGP130, soluble gp130; sCD40L, soluble CD40 ligand; SAP, serum amyloid P; TGF, transforming growth factor; PYY, peptide YY; SCF, stem cell factor; SAA, serum amyloid A; GLP, glucagon-like peptide; POR, prevalence odds ratio; CI, confidence interval; Q, quantile.

Insulin was the marker most strongly associated with self-reported diabetes ([Table 2](#pone.0182359.t002){ref-type="table"}). As there were no people with self-reported diabetes in quantile 1 (Q1), quantile 2 (Q2) was the referent group. Compared with quantile 2 (Q2) of insulin, the adjusted prevalence odds ratios (POR) for diabetes were 2.3 (95% CI: 0.5--10.1) and 12.2 (95% CI: 3.3--45.5) (*P* for trend = 0.0003) for quantiles 3 (Q3) and 4 (Q4), respectively. Compared to individuals in Q1 of GIP; PORs for diabetes were 4.0 (95% CI: 0.7--22.2), 4.2 (95% CI: 0.8--21.7) and 12.2 (95% CI: 3.3--77.2) (*P* for trend = 0.0003) for Q2, Q3 and Q4, respectively. Likewise, compared to individuals in Q1 of PP; PORs for diabetes were 1.7 (95% CI: 0.3--9.9), 9.2 (95% CI: 1.9--43.8) and 5.8 (95% CI: 1.2--28.0) (*P* for trend = 0.001) for Q2, Q3 and Q4, respectively. Following mutual adjustment, both insulin and PP, but not GIP, retained statistical significance. Similar trends were observed for GIP and PP when results were compared by individual study ([S4 Table](#pone.0182359.s004){ref-type="supplementary-material"}). The association between insulin and diabetes was observed in the NHL study, but not the ovarian cancer study.

Metabolic marker correlations and relationships among those not self-reporting a history of diabetes with inflammation-related markers associated with diabetes {#sec010}
---------------------------------------------------------------------------------------------------------------------------------------------------------------

Insulin, GIP, and PP were only measured in the NHL and ovarian cancer studies; Spearman correlation coefficients were calculated for the three markers by study. Insulin and PP were weakly correlated (0.2 for the NHL and ovarian cancer studies); however, GIP was moderately correlated with insulin (0.5 for the NHL and ovarian cancer studies) and weakly correlated with PP (0.3 for the NHL study and 0.4 for the ovarian cancer study) (Tables A-C in [S1 File](#pone.0182359.s006){ref-type="supplementary-material"}). Higher insulin levels were associated with higher CCL19, sTNFR1, amylin, and C-peptide levels on linear regression among participants who did not report a history of diabetes and with a self-reported history of diabetes on logistic regression ([S5 Table](#pone.0182359.s005){ref-type="supplementary-material"}). No other associations were observed between inflammation-related markers and insulin, GIP, or PP among people who did not report a history of diabetes.

Discussion {#sec011}
==========

In this cross-sectional study, nested within PLCO, we evaluated the largest number of systemic inflammation-, immune-, and metabolic-related markers and self-reported diabetes to date. We found that elevated levels of inflammation-related markers were associated with self-reported diabetes. Of the 78 different inflammation- and metabolic-related markers assessed, 16 were associated with diabetes at *P* \<0.05, including glucose transport and signaling pathway proteins (insulin, GIP, PP, glucagon, amylin, C-peptide), cytokines and cytokine receptors (sIL-6R, sTNFR1, STNFR2, and sIL-RII), and chemokines (CCL21, CCL20, CXCL11, CCL19, CXCL10, and CXCL6). As expected, we saw strong associations between insulin, GIP, and PP and self-reported diabetes after correction for multiple comparisons.

Inflammation and immune-related biomarkers and diabetes {#sec012}
-------------------------------------------------------

We found significant associations with self-reported diabetes for several circulating cytokines, many of which had not been previously investigated. The literature on this subject has focused largely on a few acute phase reactants and cytokines, such as CRP and IL-6. Higher levels of CRP, high sensitivity CRP (hsCRP), and IL-6 have consistently been associated with an increased risk of insulin resistance \[[@pone.0182359.ref019]--[@pone.0182359.ref021]\], hyperinsulinism \[[@pone.0182359.ref020], [@pone.0182359.ref022]\], impaired glucose tolerance \[[@pone.0182359.ref023]--[@pone.0182359.ref025]\], type 2 diabetes \[[@pone.0182359.ref010], [@pone.0182359.ref023], [@pone.0182359.ref026]--[@pone.0182359.ref030]\], and metabolic syndrome \[[@pone.0182359.ref031], [@pone.0182359.ref032]\]. Furthermore, CRP, hsCRP, and IL-6 levels decrease following medication and/or lifestyle interventions \[[@pone.0182359.ref026], [@pone.0182359.ref033]--[@pone.0182359.ref035]\].

The lack of association between these markers and self-reported diabetes in our cross-sectional study may be due to several factors including: method of cytokine measurement and/or assay variations, method of diabetes assessment, and differences in study populations. While we observed poor performance of IL-6 in our Luminex bead assay as evidenced by a low level of detection, its soluble receptor, sIL-6R, was associated with a history of self-reported diabetes. Another critical factor may have been the method by which diabetes was assessed. For our study, diabetes was collected by self-report and not according to directly applied clinical criteria.

Given that an estimated 28% of people with diabetes are unaware that they have diabetes \[[@pone.0182359.ref002]\], this method of outcome measurement may underestimate the actual presence of diabetes in this population. Thus, those with undiagnosed diabetes would have been misclassified as not having diabetes with subsequent bias of the result toward the null. The analysis of associations between metabolic marker levels (insulin, GIP, and PP) and inflammation-related markers among people not reporting a history of diabetes revealed associations between insulin and the chemokine CCL19 and the cytokine receptor sTNFR1, suggesting that there is a portion of participants unaware that they have diabetes. Finally, another important consideration is the population examined. Multiple studies have shown that associations of CRP and IL-6 with type 2 diabetes vary by race and ethnicity \[[@pone.0182359.ref036], [@pone.0182359.ref037]\], sex \[[@pone.0182359.ref027], [@pone.0182359.ref030]\], and body mass index \[[@pone.0182359.ref026], [@pone.0182359.ref036], [@pone.0182359.ref037]\].

Using data from prospective studies, pooled estimates of the associations of CRP and IL-6 with diabetes showed a 26 to \~30% increased risk of type 2 diabetes in one meta-analysis \[[@pone.0182359.ref010]\] with similar results reported in a more recent meta-analysis \[[@pone.0182359.ref038]\], indicating that inflammation is likely one component in a number of factors contributing to type 2 diabetes. Supporting this assertion are functional data linking circulating IL-6 levels with an inverse association to insulin action that was mediated through adiposity as measured by percent body fat \[[@pone.0182359.ref039]\]. Finally, even though CRP, hsCRP, and IL-6 were not associated with self-reported diabetes in our study, higher levels of receptors for pro-inflammatory cytokines, including IL-6 (sIL-6R) and tumor necrosis factor-alpha (TNF-α) (sTNFR1 and sTNFR2), showed trends for associations with self-reported diabetes, findings which are supported by prior literature for sIL-6R \[[@pone.0182359.ref019], [@pone.0182359.ref025]\] and either sTNFR1 or sTNFR2 \[[@pone.0182359.ref023], [@pone.0182359.ref026], [@pone.0182359.ref029], [@pone.0182359.ref035]\].

More recently, studies have begun to examine the relationships between diabetes and other chemokines, anti-inflammatory cytokines, and associated receptors \[[@pone.0182359.ref011]\]. We observed associations between self-reported diabetes and the chemokines previously reported in the literature, including CXCL10 and interleukin-8 (IL-8) \[[@pone.0182359.ref040]\], as well as identified a number of novel associations such as: CCL19, CCL20, CCL21, CXCL6, and CXCL11. The mechanism underlying these associations involves a complex interplay between adipocytes and the proinflammatory cytokines and chemokines that they produce, as well as the macrophages recruited to pancreatic islets that communicate via acute phase reactants, chemokines and pro-inflammatory cytokines \[[@pone.0182359.ref041]--[@pone.0182359.ref043]\].

Metabolic markers and diabetes {#sec013}
------------------------------

The strong associations between self-reported diabetes and insulin, GIP, and PP found in this study are biologically expected given the critical roles that they play in glucose transport and metabolism. Insulin plays a critical anabolic role in glucose homeostasis and energy storage by facilitating glucose uptake by liver and muscle cells as well as fat uptake by adipocytes and by inhibiting gluconeogenesis, lipolysis, and proteolysis. Hyperinsulinemia contributes to insulin resistance and to the development of type 2 diabetes \[[@pone.0182359.ref044]\]. GIP is also a regulator of insulin secretion \[[@pone.0182359.ref045]\]. Patients with type 2 diabetes have been found to have elevated basal GIP in comparison with people who do not have diabetes \[[@pone.0182359.ref046]\]. Finally, in comparison with people without type 2 diabetes and people with prediabetes, levels of PP among people with type 2 diabetes have been found to be elevated following an oral glucose tolerance test \[[@pone.0182359.ref047]\]. Furthermore, patients with type 2 diabetes who lost weight following a dietary intervention demonstrated decreased PP, increased insulin secretion, and increased glucose sensitivity \[[@pone.0182359.ref048]\]. More importantly, hyperinsulinemia and insulin resistance have been associated with both malignant and premalignant conditions \[[@pone.0182359.ref049], [@pone.0182359.ref050]\].

Strengths and limitations {#sec014}
-------------------------

This study has a number of strengths. While most studies examining inflammation markers and diabetes only measured and analyzed associations between a handful of cytokines and chemokines, this study involved the most comprehensive evaluation of systemic inflammation markers and diabetes to date. It was nested within an established, population-based cohort with standardized specimen collection methods. A large sample size increased the power of the study to detect associations. The strict statistical criteria applied for significance decreased the probability of false positive findings; however, it may have increased the probability of false negative findings and a lack of detection of smaller associations. The strong associations between metabolic-related markers, including insulin, and self-reported diabetes confirms that the assay works.

This study also has limitations. The PLCO study did not collect type of diabetes (type 1 vs. type 2) or information on insulin dependence and other treatments. Also, PLCO did not validate reports of diabetes history. However, as approximately 90 to 95% of cases of diabetes are of type 2 and given that PLCO enrolled adults between the ages of 55 and 74, the vast majority of the diabetes cases included in this analysis are likely type 2. Furthermore, several published studies, including the Women's Health Initiative (WHI), compare diabetes history by self-report with diagnoses based on medical records. WHI researchers found high positive predictive value of self-reported prevalent and incident diabetes and a high negative predictive value when diabetes is not self-reported \[[@pone.0182359.ref051], [@pone.0182359.ref052]\]. A similar comparison of self-reported diabetes and diagnoses by Canadian administrative health data found kappa coefficients ≥0.80, indicating substantial agreement \[[@pone.0182359.ref053]\].

Another concern is that a method of marker measurement in addition to the Luminex bead-based assays was not utilized. Major advantages to using such multiplex assays are the reduced sample volume required for the assay and the reduced time to perform the assays. The performance characteristics and sensitivity of these Luminex immune-, inflammation-, and metabolic-related serum markers have been tested and previously reported \[[@pone.0182359.ref014]\]. Additionally, results from this assay have been extensively analyzed in association with multiple cancer types \[[@pone.0182359.ref006], [@pone.0182359.ref015], [@pone.0182359.ref054], [@pone.0182359.ref055]\], cigarette smoking \[[@pone.0182359.ref056]\], body mass index and physical activity \[[@pone.0182359.ref057]\], and coffee consumption \[[@pone.0182359.ref058]\]. Thus, the assay methodology used in this study has been extensively evaluated and the results shown to be related to factors impacting systemic inflammation.

Markers also were not measured in all three of the substudies of the PLCO cohort (lung cancer, NHL, and ovarian cancer studies). As such, the study design precludes an assessment of inflammation markers in aggregate. Given our use of baseline data on self-reported diabetes and covariates and inflammation-related markers measured on baseline serum specimens collected predominantly at a single time point, the temporality of the association between the markers and diabetes could not be determined based on cross-sectional data. Analysis restricted to the NHL and lung cancer studies, from which all specimens analyzed were collected at baseline, revealed similar associations between self-reported diabetes and insulin and GIP. While fasting status was not collected in PLCO, analyses restricted to blood draws obtained in the morning yielded similar results. Finally, as the participants in this sample of the PLCO cohort is entirely comprised of Non-Hispanic whites, these results may not be generalizable to people of other races and ethnicities.

Future directions {#sec015}
-----------------

A number of future studies can be proposed in light of our findings. The multiplex immune assay, capable of simultaneously measuring markers with varying functions, can be applied to large-scale population-based studies comparing people with and without type 2 diabetes based on clinically documented criteria and incorporating treatment information. Such a design would allow for the examination of the relative strength of associations between type 2 diabetes and glucose metabolism and transport markers vs. that between diabetes and inflammation using an aggregate assessment of systemic inflammation via a calculated score. Given the associations reported in the literature between diabetes and diseases such as cancer, inflammation and cancer, and between diabetes and inflammation, formal mediation analysis in a prospective longitudinal study could provide greater insights into the relative sequence of contributing factors to cancer development.

Conclusions {#sec016}
===========

In conclusion, we evaluated a large number of systemic inflammation-, immune, and metabolic-related markers among people with self-reported diabetes to date and found that in addition to having strong associations with metabolic markers, self-reported diabetes was also nominally associated with elevated levels of numerous cytokines, chemokines, and their receptors. Additional prospective studies are needed to assess the relationships between inflammation and diabetes to ascertain directionality of the associations and their contributions to the development of chronic diseases such as cancer.
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